Johnson & Johnson submitted an application for Emergency Use Authorization of its COVID-19 vaccine candidate to the United States Food & Drug Administration. An outside advisory panel will meet February 26^th to determine whether approval should move forward, and if it does the vaccine could be available in the United States for early March. Johnson & Johnson’s candidate showed strong results in clinical trials, with 85% effectiveness in preventing severe disease in the US, South Africa and Latin America. However there were regional differences in preventing moderate to severe infection, with 57% effectiveness in South Africa where a local variant is dominant compared to 72% in the US. The application seeks approval for a single dose regimen of vaccine, which would differ from those currently in use which require two shots.